Observational study on the natural history of uveal melanoma
A Prospective Natural History Study in Uveal Melanoma
This study is collecting information from people with uveal melanoma to better understand how the disease progresses and to help develop new treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 700 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Columbia University Academic / other |
| Drugs / interventions | radiation |
| Locations | 17 sites (Boston, Massachusetts and 16 other locations) |
| Trial ID | NCT04588662 on ClinicalTrials.gov |
What this trial studies
This study aims to create a multicenter registry to collect prospective data on uveal melanoma (UM) to better understand its natural history. It involves a multidisciplinary approach, capturing data from diagnosis through treatment and surveillance for recurrence. The registry will provide valuable insights that could support the development of new therapies for UM. By documenting the complete course of the disease, the study seeks to fill a significant gap in current knowledge about UM management.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with uveal melanoma who can provide informed consent.
Not a fit: Patients who do not have a diagnosis of uveal melanoma will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and treatment options for patients with uveal melanoma.
How similar studies have performed: This study is novel as there are currently no ongoing multi-center natural history studies for uveal melanoma.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria * Diagnosis of uveal melanoma * Ability to provide written informed consent for participation in the prospective registry OR an institutional waiver by the IRB/ethics committee for retrospective data collection without written informed consent Exclusion Criteria \*None
Where this trial is running
Boston, Massachusetts and 16 other locations
- Massachusetts General Hospital — Boston, Massachusetts, United States (Not_yet_recruiting)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (Recruiting)
- Thomas Jefferson University Hospital — Philadelphia, Pennsylvania, United States (Recruiting)
- MD Anderson Cancer Center — Houston, Texas, United States (Recruiting)
- Royal Adelaide Hospital — Adelaide, Australia (Recruiting)
- Chatswood Eye Specialists — Chatswood, Australia (Recruiting)
- Royal Victorian Eve and Ear Hospital — East Melbourne, Australia (Not_yet_recruiting)
- Western Eye Specialists — Maribyrnong, Australia (Recruiting)
- Pennington Eye Clinic — North Adelaide, Australia (Recruiting)
- Perth Retina — Subiaco, Australia (Recruiting)
- Dr. Conway Private Rooms — Sydney, Australia (Recruiting)
- St. Vincent's Hospital — Sydney, Australia (Recruiting)
- Princess Margaret Cancer Center — Toronto, Canada (Recruiting)
- Erlangen — Erlangen, Germany (Not_yet_recruiting)
- Clatterbridge Cancer Centre — Birkenhead, United Kingdom (Recruiting)
- Mount Vernon Cancer Centre — Northwood, United Kingdom (Not_yet_recruiting)
- Sheffield — Sheffield, United Kingdom (Not_yet_recruiting)
Study contacts
- Principal investigator: Shaheer Khan, DO — Columbia University
- Study coordinator: Research Nurse Navigator
- Email: cancerclinicaltrials@cumc.columbia.edu
- Phone: 212-342-5162
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.